Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of…
Prostate Cancer Translational Research Group
Approximately 10% of patients with metastatic castration-resistant prostate cancer have alterations in the BRCA1 or BRCA2 genes which are associated…
PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients…
